All In Biotech

Drug Trial Radar · NCT06715540

Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

An Open-Label, Non-Comparative Study of the Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses of BCD-261 After Single Subcutaneous Injection in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Mar 29, 2024

Primary completion

Feb 2025

Study completion Dec 2025

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses to healthy male subjects aged from 18 to 45 years old. The study consists of the first stage (dose escalation) and the second stage (dose expansion).

Conditions

  • Healthy

Interventions

  • BCD-261, dose 1Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, dose 2Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, dose 3Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, dose 4Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, dose 5Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, dose 6Drug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, pre-specified therapeautic dose XDrug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

  • BCD-261, pre-specified therapeautic dose XDrug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

  • BCD-261, pre-specified therapeautic dose YDrug

    Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with adverse reactionsTime frame: 127 days
  2. Proportion of subjects with serious adverse reactionsTime frame: 127 days
  3. Proportion of subjects with CTCAE 5.0 grade 3 or higher adverse reactionsTime frame: 127 days
  4. Proportion of subjects who prematurely withdrew from the study due to adverse reactionsTime frame: 127 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • "Meditsinskiy teсhnologiy Maly"

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.